Hims & Hers Health Inc. Stock News

Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-home cancer screening, and is in renewed talks with Novo Nordisk for oral Wegovy distribution. Management guides for robust 4Q25 and full-year 2025 revenue and EBITDA, with international expansion an...

Hims & Hers Health, Inc. ( HIMS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conference Call Participants Justin Patterson - KeyBanc Capital Markets Inc., Research Division Maria Ripps - Canaccord Genuity Corp., Research Division Craig Hettenbach - Morgan Stanley, Research Divi...

Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.

The telehealth platform said revenue rose 49% to $599 million in the latest quarter.

Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and reduced unit sales in the telehealth company's weight-loss business.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. “This quarter we continued to prove that our vision of helping tens of millions of people around the world a...

Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out after the close Monday, Nov. 3. Since hitting a February record high of $72.98, the stock has staged several rallies that have run out of steam around $65.